Enhertu's Triumph: AstraZeneca and Daiichi Sankyo Unveil Pivotal Phase 3 Data, Reshaping Cancer Care
FDA Approves Tezspire Self-Administration, Revolutionizing Severe Asthma Care for Amgen and AstraZeneca
Roche's Bold Leap: Pioneering Direct Patient Engagement for Enhanced Care
The Biotech Bonanza: Unearthing Tomorrow's Investment Gems in a Volatile Market
UK's Controversial Drug Price Hike: Pharma Giants Hit the Brakes on Investment
A New Horizon in Breast Cancer Treatment: AstraZeneca's Datroway Extends Lives and Boosts Hopes
A New Horizon for Breast Cancer: Enhertu Shows Groundbreaking Survival Benefit in HER2-low Metastatic Patients
The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?
A Pivotal Moment: HHS Advances Major Drug Pricing Rule for Review
Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks
Trump's Bold Play: Delaying Pharma Tariffs for Deeper Drug Price Deals
Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape
Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs
AstraZeneca's Bold Leap: Simplifying US Investment with a Direct Nasdaq Listing
AstraZeneca's Bold Leap: Transforming Patient Access with New Direct-to-Consumer Platform
Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule
European Experts Back Two AstraZeneca Breakthroughs: New Hope for Rare Diseases
Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave
AstraZeneca's Baxdrostat: A Beacon of Hope in the Fight Against Uncontrolled High Blood Pressure
The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?
First RSV shots, groundbreaking gene therapy among 2024 drugs to watch